Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Cancer Oncology

Medicine

Paleontology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(19)30151-2